Get started
Author

Tin‐Yun Tang

Expanding the Diversity of Mycobacteriophages: Insights into Genome Architecture and Evolution
2011 · Welkin H. Pope, Deborah Jacobs-Sera, et al. · PLoS ONE · 154
PDF
Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers
2024 · Natalie Y L Ngoi, Tin-Yun Tang, et al. · The Oncologist · 39
PDF
Comparative Genomic Analysis and Clinical Outcomes of BRAF -mutated Advanced Biliary Tract Cancers
2023 · Tin-Yun Tang, Federico Nichetti, et al. · Clinical Cancer Research · 17
Associations of Racial and Ethnic Category, Age, Comorbidities, and Socioeconomic Factors on Concordance to NCCN Guidelines for Patients With High-Risk Biliary Tract Cancers After Surgery
2022 · Lauren F. Huang, Augustine Hong, et al. · Frontiers in Oncology · 8
PDF
Cis-acting single nucleotide polymorphisms alter MicroRNA-mediated regulation of human brain-expressed transcripts
2016 · Shyam Ramachandran, Stephanie L. Coffin, et al. · Human Molecular Genetics · 7
PDF
Idiopathic chronic pancreatitis treated with ivacaftor in a CFTR carrier with methylmalonic acidemia
2021 · Tin-Yun Tang, Vincent B. Cruz, et al. · Journal of Cystic Fibrosis · 6
Adoption of single agent anticancer therapy for advanced hepatocellular carcinoma and impact of facility type, insurance status, and income on survival: Analysis of the national cancer database 2004–2014
2021 · Aman Opneja, Gino Cioffi, et al. · Cancer Medicine · 6
PDF
Genomic profile of intrahepatic cholangiocarcinoma with MTAP loss.
2022 · Tin-Yun Tang, Jeffrey S. Ross, et al. · Journal of Clinical Oncology · 5
Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson
2026 · Jeong Uk Lim, Heather Y. Lin, et al. · npj Precision Oncology · 3
PDF
Germline Mutations as Cancer Drug Targets
2025 · Tin-Yun Tang, Karen Colbert Maresso, et al. · Cancer Discovery · 3
Case Report: Durable Response to Very Low Dose Tyrosine Kinase Inhibitors in Advanced Hepatocellular Carcinoma
2021 · Tin-Yun Tang, Katherine Daunov, et al. · Frontiers in Oncology · 3
PDF
Bispecific Antibodies in Solid Tumors: Mechanistic Insights, Clinical Advances, and Future Directions
2026 · Radiya Almosa, Megan Macalalad Mendoza, et al. · Journal of Immunotherapy and Precision Oncology · 1
Telemedicine as a gateway to early-phase oncology trials: lessons from 14 000 patients and future directions for global access and equity
2026 · Carlos Torrado, Clark R Andersen, et al. · The Oncologist · 1
Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit
2025 · Camila Braganca Xavier, Clark R. Andersen, et al. · Cancer Research Communications · 1
PDF
Outcomes of early-onset vs average-onset colorectal cancer patients on phase I matched and non-matched therapies
2026 · Daniel A. Fox, Deepak Bhamidipati, et al. · npj Precision Oncology
PDF
Clinical determinants of survival outcomes and acute toxicity after adoptive cellular therapy for solid tumors
2026 · Jeong Uk Lim, Derrick Tao, et al. · Frontiers in Immunology
PDF
54Therapeutic Targeting of IDHl Mutations in Intrahepatic Cholangiocarcinoma Arising in Oilier Disease
2026 · Monica Hsiang, Mohamed Nuh, et al. · The Oncologist
The phase I therapeutic landscape in pancreatic ductal adenocarcinoma: Molecular profiling and emerging strategies.
2026 · Fen Saj, Camila Braganca Xavier, et al. · Journal of Clinical Oncology
PDF
Biomarker study of BND-22 in combination with cemiplimab in solid tumors.
2026 · Mohamed H. Derbala, Cara L. Haymaker, et al. · Journal of Clinical Oncology
PDF
Clinicopathologic and molecular characterization of ARID1A -mutant solid tumors using paired tissue and liquid biopsy sequencing.
2026 · Tejaswini Reddy, Lei Kang, et al. · Journal of Clinical Oncology
Abstract LB429: Impact of severe liver metastases on clinical response to immunotherapy in solid tumors
2026 · Jibran Ahmed, Bettzy Stephen, et al. · Cancer Research
Supplementary Table 1 from Germline Mutations as Cancer Drug Targets
2025 · Tin-Yun Tang, Karen Colbert Maresso, et al.
Supplementary Table 2 from Germline Mutations as Cancer Drug Targets
2025 · Tin-Yun Tang, Karen Colbert Maresso, et al.
Data from Germline Mutations as Cancer Drug Targets
2025 · Tin-Yun Tang, Karen Colbert Maresso, et al.
532 A phase 1 dose escalation and dose expansion trial of NP-101 in patients with advanced solid tumors
2025 · Camila Braganca Xavier, Bettzy Stephen, et al. · Regular and Young Investigator Award Abstracts
PDF
Works count: 59
Citation count: 253
H-index: 6
I10-index: 3
Year
Topic
Type